Bayer drug gets orphan label

Share this article:
Bayer drug gets orphan label
Bayer drug gets orphan label

Bayer HealthCare landed an orphan-drug designation for its experimental inhaled ciprofloxacin dry powder, designed to treat patients with non-cystic fibrosis bronchiectasis.

The condition, which occurs in patients who do not have cystic fibrosis, refers to bronchial tube scarring and inflammation, which make it difficult to clear mucous. The British Lung Foundation estimates that around 25% of cases have no known cause, but some cases are associated with scarring caused by whooping cough or pneumonia and reduced immunity after an infection, among other causes.

Symptoms include recurring infections and a persistent cough.

Bayer's proposed treatment is for intermittent use.

Recently approved orphan drugs include the likes of Eli Lilly's oncology treatment Cyramza.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...